期刊文献+

氟康唑、伊曲康唑、特比萘芬治疗系统性普通裂褶菌感染小鼠模型的观察 被引量:3

Therapy of Fluconazole,Itraconazole,Terbinafine in Mice Model with Systemic Infection of Schizophyllum commune
下载PDF
导出
摘要 目的观察氟康唑、伊曲康唑、特比萘芬治疗系统性普通裂褶菌感染的疗效。方法建立小鼠系统性普通裂褶菌感染模型,观察给药后小鼠的生存率、中位生存时间、组织逆培养阳性率、肝脏组织载菌量。结果氟康唑组、伊曲康唑组、特比萘芬组、生理盐水对照组小鼠21d观察期内生存率分别为64.00%,68.00%,20.00%,12.00%;中位生存时间分别为>21d,>21d,11d和8d;肝脏组织逆培养阳性率分别为60.00%,68.00%,100.00%,100.00%;肝脏组织载菌量分别为19.533±4.121,20.706±5.193,32.920±8.485,36.520±9.138。结论氟康唑和伊曲康唑在小鼠体内均有较好的抗普通裂褶菌活性,而特比萘芬效果较差,氟康唑与伊曲康唑之间无疗效差别。 Objective To investigate the efficacy of Fluconazole, Itraconazole, Terbin tne for systemic infection of SchizophyUum commune in mice model. Methods Mice model suffered from systemic infection of Schizophyllum commune were established on and their survival rates, median survival time, Fungal retro-culture, fungal burden of liver of mice were observed after administration. Results During the observation period, the survival rates of Fluconazole group, Itraconazole group, Terbinafine group and control group were 64.00% ,68.00% ,20.00% ,12.00% respectively;the median survival time were 〉21d, 〉21d,lld and 8d; Fungal retro-cuhure of liver were 60.00% ,68.00% , 100.00%, 100.00% ; fungal burden of liver were 19. 533 ±4. 121,20.706±5. 193,32. 920± 8. 485,36. 520 ±9. 138. Conclusion Fluconazole and ltracon- azole show good activity against Schizophyllum commune in vivo, Terbinafine is ineffective in vivo. There are no significant difference between the therapy of Fluconazole and hraconazole .
出处 《中国皮肤性病学杂志》 CAS 北大核心 2011年第6期415-418,共4页 The Chinese Journal of Dermatovenereology
关键词 氟康唑 伊曲康唑 特比萘芬 普通裂褶菌 系统性 感染 小鼠 Fluconazole Itraconazole Terbinafine Schizophyllum commune, systemic Infection Mouse
  • 相关文献

参考文献2

二级参考文献25

  • 1赵弋清,罗霞,陈东辉,余梦瑶,杨志荣.不同剂量环磷酰胺诱导正常小鼠免疫抑制的对比研究[J].免疫学杂志,2005,21(B06):122-124. 被引量:82
  • 2黄琼,李志,黄建康,杨杏芬,黄俊明,蔡玟.CD69^+/NKG2D^+比值在保健食品评价中应用[J].中国公共卫生,2005,21(9):1095-1096. 被引量:4
  • 3沈玉光,许金良,杨宗林,赵婷茹.流式细胞术测肺癌患者外周血T细胞亚群及其与临床病理的关系[J].实用诊断与治疗杂志,2006,20(2):101-102. 被引量:22
  • 4Czaika V, Tietz HJ, Schmalreck A,et al. Antifungal susceptibility testing in chronically recurrent vaginal candidiasis as basis for effective therapy[J]. Mycoses,2000, 43 ( suppl 2): 45 - 50.
  • 5Evans EG. Resistance of candida species to antifungal agent used in the treatment of onychomycosis: a review of current problems [J]. Br J Dermatol, 1999, 141 ( Suppl 56): 33 - 35.
  • 6Mosquera J, Sharp A, Moore CB ,et al. In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp [J]. J Antimicrob Chemother, 2002, 50 ( 2 ): 189 -194.
  • 7Te Dorsthorst DT, Verweij PE, Meis JF,et al. Comparison of fractional inhibitory concentration index with response surface modeling for characterization of in vitro interaction of antifungals againt itraconazole - susceptible and resistant Aspergillus fumigatus isolates [J]. Antimicrob Agents Chemother,2002,46 ( 3 ) :702 - 707.
  • 8Weig M, Muller FM. Synergism of voriconazole and terbinafine against candida albicans isolates from human immunodeficiency Virus-infected patients with oropharyngeal candidiasis [ J ]. Antimicrob Agents Chemother,2001,45 ( 3 ): 966 - 968.
  • 9Ghannoum MA, Elewski B. Successful treatment of fluconazole - resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine [J]. Clin Diagn Lab Immuuol, 1999,6 ( 6 ): 921 - 923.
  • 10Andes D, Marchillo K, Conklin R,et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis[J]. Antimicrob Agents Chemother,2004,48 ( 1 ): 137 - 142.

共引文献50

同被引文献15

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部